This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
This Website Uses Cookies By closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
With active ingredients like cannabinoids in the mix, cannabis consumers seek standardized, reliable levels of cannabidiol (CBD) and tetrahydrocannabinol (THC) in retail products. Consumers need to know what to expect—both in terms of the intended physiological effect and incumbent health and wellness benefits.
Open Book Extracts and Case Western Reserve University School of Medicine have entered into an agreement to explore the mechanistic effects of cannabinoids on brain cell functions.
Willow Biosciences Inc. says it has successfully developed a scalable process for producing cannabigerol (CBG) with greater than 99 percent purity, no detectable THC and demonstrated production at 500-litre scale.
With greater than 98% potency, small particle size and a mild natural terpene flavor and odor, this CBG isolate is ideal for a variety of applications, including beverages, gummies, capsules, tinctures and topicals.